Group 1 - The core point of the article is that 乐心医疗 (Lixun Medical) has disclosed the draft of its "Key Stone No. 1" employee stock ownership plan, which aims to involve a maximum of 25 participants [1] - The employee stock ownership plan intends to hold a maximum of 912,200 shares, with a total fundraising cap of 6.9419 million yuan [1] - The duration of the employee stock ownership plan is set for 48 months, with different lock-up periods of 12 months and 24 months for the acquired shares [1]

Core Viewpoint - Le Xin Medical (300562.SZ) has disclosed a draft for its 2025 stock option incentive plan, aiming to motivate its employees through stock options [1] Group 1: Stock Option Details - The company plans to grant a total of 2 million stock options to 40 incentive recipients [1] - The exercise price for the stock options is set at 15.21 yuan per option [1] - The validity period of the incentive plan is from the date of stock option authorization until all granted options are exercised or canceled, with a maximum duration of 36 months [1]

Group 1 - The core point of the article is that 乐心医疗 (Leksin Medical) has disclosed the draft of its "基石1号" employee stock ownership plan, which involves a maximum of 25 participants and aims to hold up to 912,200 shares [1] - The total amount of funds to be raised by this employee stock ownership plan is capped at 6.9419 million yuan [1] - The duration of the employee stock ownership plan is set for 48 months, with different lock-up periods for the acquired shares, specifically 12 months and 24 months, starting from the date the plan is approved by the company's shareholders' meeting [1]

Core Viewpoint - 乐心医疗 has announced a stock option incentive plan for 2025, aiming to motivate its employees through equity participation [1] Summary by Categories Stock Option Plan - The company plans to grant a total of 2 million stock options to 40 incentive recipients [1] - The exercise price for the stock options is set at 15.21 yuan per option [1] - The validity period of the incentive plan is from the date of stock option authorization until all granted options are exercised or canceled, with a maximum duration of 36 months [1]

Core Viewpoint - Recent actions by the company regarding its stock incentive plan include the repurchase and cancellation of restricted stocks for a departing employee, along with adjustments to the second vesting period of the 2023 stock incentive plan [1][3]. Group 1: Incentive Plan Implementation History - On July 24, 2023, the company’s Compensation and Assessment Committee proposed the draft of the incentive plan, which was later approved by the board on July 26, 2023 [2]. - The company publicly announced the list of incentive recipients and held a temporary shareholders' meeting on August 18, 2023, to approve related resolutions [2]. - Subsequent meetings in 2024 and 2025 involved discussions and approvals regarding adjustments to grant prices and conditions for lifting restrictions on the stocks [2]. Group 2: Details of Repurchase and Cancellation - The repurchase and cancellation of restricted stocks are triggered by the departure of an incentive recipient, who no longer meets the incentive conditions [3]. - The repurchase price will be at the grant price, and the funds for this repurchase will come from the company’s own resources [4]. Group 3: Adjustments to Lifting Restrictions - Originally, two individuals were eligible to lift restrictions on 1.04 million shares, but due to the departure of one individual, the number of eligible individuals is now one, and the shares eligible for lifting restrictions have been adjusted to 1 million [5]. - Legal opinions confirm that the repurchase and adjustment of lifting restrictions have received necessary authorizations and approvals, although final approval from the shareholders' meeting is still required [5].

Company Changes - Huang Linxiang resigned from her positions as employee representative director and CFO due to personal reasons, and will no longer hold any positions in the company or its subsidiaries [1] - Wu Rong has been appointed as the new CFO after being nominated by the general manager and approved by the board's nomination and audit committees [1] Financial Performance - For the first half of 2025, the revenue composition of the company is as follows: home medical products accounted for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - The current market capitalization of the company is 3.2 billion yuan [1]

Group 1 - The core point of the news is that 乐心医疗 (Lixun Medical) announced a board meeting to discuss the authorization of a stock option incentive plan for 2025 [1] - For the first half of 2025, the revenue composition of 乐心医疗 is as follows: home medical products account for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - As of the report, 乐心医疗 has a market capitalization of 3.2 billion yuan [1]

乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-095 广东乐心医疗电子股份有限公司 关于回购注销部分限制性股票的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 公司 2023 年限制性股票激励计划（以下简称"本激励计划"）授予第一类 限制性股票的 1 名激励对象因离职不再符合激励条件，公司将回购注销其已获授 但尚未解除限售的第一类限制性股票 40,000 股。 广东乐心医疗电子股份有限公司（以下简称"公司"）于 2025 年 9 月 9 日 召开的第五届董事会第五次会议审议通过了《关于回购注销部分限制性股票的议 案》，上述议案尚需提交股东会审议。现有关具体情况公告如下： 一、本次激励计划已履行的决策程序和批准情况 1、2023 年 7 月 26 日，公司召开第四届董事会第八次会议，审议通过了《关 于<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于<2023 年限制 性股票激励计划实施考核管理办法>的议案》以及《关于提请股东大会授权董事 会办理公司股权激励计划相关事宜的议案》等议案， ...

乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-094 广东乐心医疗电子股份有限公司 关于2023年限制性股票激励计划第一类限制性股票 第二个解除限售期解除限售条件成就的公告（调整后） 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、公司 2023 年限制性股票激励计划（以下简称"本激励计划"）授予的第 一类限制性股票第二个解除限售期可解除限售人数由 2 人调整为 1 人，可解除限 售的第一类限制性股票由 104.00 万股调整为 100.00 万股，调整后可解除限售的 第一类限制股票数量占公司目前总股本（本公告披露日的总股本为 218,201,988 股）的 0.46%； 2、本次拟解除限售的第一类限制性股票的来源为公司向激励对象定向发行 的人民币 A 股普通股股票； 3、本激励计划第一类限制性股票的授予日为 2023 年 8 月 18 日，登记完成 日为 2023 年 9 月 22 日，第二个限售期为登记完成日起的 24 个月。第二个限售 期即将届满，公司将在第二个限售期届满、进入第二个解除限 ...

| 15 | 上市公司全部在有效期内的股权激励计划所涉及的标的股票总 | 否 | | --- | --- | --- | | | 数累计是否超过公司股本总额的20% | | | 16 | 单一激励对象累计获授股票是否超过公司股本总额的1% | 否 | | 17 | 激励对象预留权益比例是否未超过本次股权激励计划拟授予权 益数量的20% | 否 | | 18 | 激励对象为董事、高级管理人员、单独或合计持股5%以上股东 或实际控制人及其配偶、父母、子女以及外籍员工的，股权激 | 是 | | | 励计划草案是否已列明其姓名、职务、获授数量 | | | 19 | 激励对象为董事、高管的，是否设立绩效考核指标作为激励对 | 是 | | | 象行使权益的条件 | | | 20 | 股权激励计划的有效期从授予日起计算是否未超过10年 | 是 | | 21 | 股权激励计划草案是否由薪酬与考核委员会负责拟定 | 是 | | | 股权激励计划披露完整性要求 | | | 22 | 股权激励计划所规定事项是否完整 | 是 | | | （1）对照《股权激励管理办法》的规定，逐条说明是否存在上 市公司不得实行股权激励以及激励对象不得 ...